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Psoriasis is an immune mediated chronic inflammatory disease of unknown etiology and characterized by
epidermal hyperplasia and inappropriate immune activation, which affects the skin and joints as well.The
immunopathogenesis of psoriasis involves changes in the innate and acquired (T lymphocytes) immune system.
The cells of the innate immune system when activated produce growth factors, cytokines, and chemokines that act
on cells of the acquired immune system and vice versa, being characterized as atype 1 immune response disease.
Fish oil n-3 polyunsaturated fatty acids, mainly eicosapentaenoic (EPA), and docosahexaenoic acids (DHA), reduce
symptoms in many inflammatory skin diseases. The mechanism of action of fish oil in the treatment of psoriasis is
widely based on the alteration of epidermal and blood cell membrane lipid composition. In the present study, we
performed a review of the several studies, which analyzed the action of n-3 polyunsaturated fatty acids in patients
with psoriasis. Taken together, the majority of the studies showed that n-3 polyunsaturated fatty acids, mainly from
marine origin, have beneficial effects and can be utilized as adjuvant therapy in psoriasis treatment. Both oral and
intravenous administration of fish oil n-3 polyunsaturated fatty acids had positive effects. However, further studies
are warranted to answer many intriguing questions, for instance, the ideal quantity of fish oil to be utilized, the
effect on different forms and severity of psoriasis and last, but not least, the consequences of using fish oil n-3
polyunsaturated fatty acids on the cardiovascular features of patients with psoriasis.
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Psoriasis is an immune-mediated chronic inflammatory
disease of unknown etiology and characterized by epider-
mal hyperplasia and inappropriate immune activation,
which affects the skin and joints as well. In the skin, it is
characterized by multiple erythematous scaly lesions
where well-defined plaques arise mainly in the elbows,
knees, scalp, navel, and lower back, but it is possible that
the disease spreads throughout the body in a systemic way
as erythroderma: [1–3]. In the joints, it attacks the inser-
tions of tendons by provoking pain and inflammation
followed by a joint deformity, especially in small joints [2].
Psoriasis affects both sexes and people of all ages exhibit-
ing peaks of incidence in adulthood (75% of the patients
before 40 years of age) [3, 4]. It is a disease with bimodal* Correspondence: dichi@sercomtel.com.br
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Clinical manifestations of psoriasis are different; they
may vary from a limited disease to a very extensive skin
lesion and is characterized by periods of remissions and
exacerbations [5]. The clinical forms of psoriasis include
vulgar or plaque, guttate, erythrodermic, and pustular.
Psoriasis vulgaris affects approximately 85 to 90% of all
patients with the disease; scaly, erythematous plaques
develop in a fairly symmetrical distribution. Any part of
the skin may be affected; the most common sites are the
scalp, elbows, knees, shins, umbilicus, sacrum, and geni-
talia. Plaques may range in size from a few millimeters
to a large part of the trunk or limb. Guttate psoriasis is
characterized by small scaly erythematous papules and
predominates in the members but not on palms and
soles, usually occurring in adolescents or younger adults
often after infectious conditions. Erythrodermic psoriasis
affects more than 90% of body surface with scales and
intense sub acute or chronic erythema and overall poorle is distributed under the terms of the Creative Commons Attribution 4.0
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plaques or generalized pustular form and possibly as an
early manifestation of the disease. At last, the pustular
psoriasis, this can have a local or generalized presenta-
tion. Whereas the local form is characterized by papules
and/or erythematous plaques usually limited to the
palms and/or plants (palmar-plantar pustular psoriasis)
that occurs in adults, most commonly in females, the
generalized pustular psoriasis is characterized by sterile
pustules, with fever and overall poor health such as body
pain and diarrhea. Mostly, it occurs in patients with
psoriasis plaque, after exposure with aggravating factors,
such as hypocalcemia, interruption of systemic cortico-
steroid therapy, infection, and untimely topical therapy
[3, 4].
The relationship between psoriasis and other diseases has
drawn increasing interest in recent years. Growing evidence
suggests that cardiovascular disease, obesity, diabetes,
hypertension, dyslipidemia, and metabolic syndrome are
found at a higher prevalence in psoriasis patients when
compared with the general population. These associations
between psoriasis and these diseases may be due to the sys-
temic inflammatory mediators, which are generated in all
aforementioned conditions [6].
Immunopathogenesis of psoriasis
The immunopathogenesis of psoriasis involves changes
in the innate and acquired (T lymphocytes) immune
system. The cells of the innate immune system when
activated produce growth factors, cytokines, and
chemokines that act on cells of the acquired immune
system and vice versa, being characterized as a type 1
immune response disease, such as diabetes mellitus and
multiple sclerosis [7, 8].
Normally, the skin renewal occurs around 28 to
30 days with the formation of new cells on its lower
layer and with the ripening, migrates to the top layer of
skin dropping in an unnoticed way. In psoriasis, the cell
cycle changes fast and can be reduced to 4 days. These
altered cells accumulate composing whitish plates
with erythroderma originating typical lesions of the
disease [9].
There is activation of the innate immune system cells
(dendritic cells and keratinocytes). Several environmen-
tal factors such as mechanical trauma, infections, drugs,
emotional stress, or even change of the own skin in the
constitution of keratinocytes are considered triggers of
the disease [1]. The mechanical trauma, for example,
can activate keratinocytes in the same way that the
binding of antigens of infectious agents to toll-like
receptors in dendritic cells and keratinocytes can lead
to their activation, producing several chemokines, cyto-
kines, interleukin 1 (IL-1), TNF-α, growth factors, and
heat shock proteins [8].In addition, in the dermis, T cells interact with macro-
phages and dendritic cells, forming new “immunological
synapse”. This interaction leads to the production of
many cytokines, which maintain and amplify the inflam-
matory process [7].
The dendritic cells and the activated macrophages pro-
duce IL-12 and IL-23. IL-12 promotes the proliferation of
Th1 and Th17 the enhancement of IL-23. The proliferation
of Th1 and Th17 in psoriasis is also attributed to the de-
crease in regulatory T cells [10].The dermal dendritic cells
also work functioning as APC to T cells and inflammatory
cells, producing IL-20, IL-23, and TNF-α. The IL-20 stimu-
lates the proliferation of keratinocytes, IL-23 promotes the
proliferation of Th17 and IL-22, IL-17, TNF-α and IL-6.
Keratinocytes also work functioning as pro-inflammatory
cells and produce cytokines, such as TNF-α, IL-1, IL-6, and
IL-8 [10, 11].
Fish oil and psoriasis
Humans, with the exception of long chain fatty acids
omega-3 (n-3) and omega-6 (n-6), which are called essen-
tial, can synthesize many of the fatty acids. Omega-6 fatty
acids as arachidonic acid (AA) can be synthesized by
humans from linoleic acid (C18:2n−6, LA), where as
omega-3 fatty acids represented by eicosapentaenoic
(EPA), docosapentaenoic (DPA), and docosahexaenoic
acids (DHA) are synthesized from α-linolenic acid
(C18:3n−3, ALA) [12, 13]. LA is found in the oils of
safflower, grape seed, poppy seed, sunflower, hemp, corn,
wheat germ, cottonseed, and soybean [13], whereas ALA
is found mainly in oils of canola, linseed and soy. How-
ever, the most important natural sources of omega-3 are
marine organisms (fish, seafood, algae) that are fed directly
or indirectly from marine phytoplankton, the primary
producer of omega-3 [12].
Omega-3 fatty acids, EPA and DHA, reduce symptoms
in many inflammatory skin diseases [14]. The mechanism
of action of fish oil in the treatment of psoriasis is widely
based on the alteration of epidermal and blood cell mem-
brane lipid composition. The arachidonic acid (AA) is
found in high levels in psoriatic skin lesions, and its metab-
olite, leukotriene B4, is considered the principal mediator
of inflammation in psoriasis [15]. When cyclooxygenase or
lipoxygenase, or both, in the place of AA in cell membranes
metabolize EPA, it may help to attenuate inflammation.
The metabolites of EPA, including leukotriene B5, are far
less potent inflammatory mediators than the degradation
products of AA [16]. The addition of fish oil to the diet of
psoriasis patients leads to an increasing of the plasma and
platelet EPA-to-AA ratios and to a significant in vitro
decrease in leukotriene B4 synthesis by neutrophils [15].
Furthermore, fish oil has not just anti-inflammatory
effects on cell membrane and eicosanoid synthesis, but
it has also regulatory effect on the epigenetics. There are
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acids, in particular n-3 polyunsaturated fatty acids, can
modify the epigenome. However, there is a need for rigor-
ous investigations to assess directly the effect of epigenetic
modifications induced by fatty acids on gene function and
metabolism and its relation with inflammatory conditions,
such as psoriasis [17, 18].
Soyland et al. [19] conducted a 4-month, double-blind,
randomized, placebo-controlled, multicenter trial among
145 patients with moderate-to-severe plaque psoriasis.
The patients were randomly assigned to either the fish-oil
group, in which each patient received six capsules daily
(each capsule had 1 g of omega-3 fatty acids(51% EPA,Table 1 Fish oil in the treatment of psoriasis
Study Type of study No. of
patients
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ultraviolet B32% DHA) or to the control group in which each patient
received six capsules of corn oil daily (each capsule con-
taining 1 g of omega-6 fatty acids (26% oleic acid, 56%
linoleic acid); the score of the Psoriasis Area and Severity
Index (PASI) levels did not change significantly in either
group at the end of the trial. No clinically important
difference was found between groups when subparts of
the PASI score were analyzed. However, fish oil group had
a significant increasing in the ratio of EPA to AA in serum
phospholipids and an increase in the ratio of polyunsatur-
ated to saturated fatty acids (Table 1).
In another study, 32 patients with chronic stable
plaque psoriasis were instructed to continue with theirDuration Results Ref.
(5 g EPA + DHA) vs
oil
4 months No significant change in PASI,
increasing in the ratio of EPA to
AA in serum phospholipids
[19]
(1.8 g EPA) vs
oil
12 weeks Significantly better improvement
in itching, erythema, scaling in
the group fish oil, no significant
change in the group olive oil
[20]
d 2.2 g DHA per 8 weeks Significant improvement only in
the 1 patient with pustular
psoriasis
[21]
ish oil (3.6 g of EPA







decrease in total TBSA and
greater clinical improvement vs
olive oil group
[22]
640 mg daily EPA/
lcitol vs control
citol only
8 weeks Omega-3 group significantly
reduces PASI, injury scalp, itching,
erythema, scaling and infiltration.
[14]
g EPA + 3.6 g DHA)
topical
one dipropionate
9 weeks No significance difference
between fish oil and placebo
[23]
ion 200 ml/day
th EPA and DHA)
fatty acids emul-
DHA < 0.1 g/
14 days PASI scores decreased by 11.2 ±
9.8 in the omega-3 group
[16]
ion 100 ml/day
PA and 21 g DHA)
-6 lipid emulsion
< 0.1 g/100 ml)
10 days Greater improvement in
erythema, infiltration,
desquamation in omega-3 group
compared with omega-6 group
[24]
oil (15.8% EPA +
vs liquid paraffin
4 weeks Significantly improvement in
scale score and thickness fish oil
treated group
[25]
ga-3 (1 or 10%) vs 8 weeks No statistically significant
difference between omega-3 and
placebo group
[26]
soriasis Area and Severity Index; TBSA, total body surface area; UVB,
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to receive either 10 capsules fish oil daily containing
1.8 g EPA, or 10 capsules of olive oil. The treatment
lasted for 12 weeks with assessments at 0, 4, 8, and
12 weeks. After 8 weeks treatment, there was a signifi-
cant lessening of itching, erythema, scaling in the group
treated with fish oil. No change occurred in the olive oil
group [20]. In a third open study that included twenty-
six patients with psoriasis, twenty-four had plaque-type
psoriasis vulgaris, one had generalized pustular psoriasis,
and one had palmo plantar pustulosis. The patients were
instructed to take 18 capsules of EPA daily (3.2 g of EPA
and 2.2 g of DHA per day), in addition to their regular
daily diet for 8 weeks. No clinically significant improve-
ment after fish oil supplementation in 8 weeks was
found, although a single patient with pustular psoriasis
showed significant improvement [21].
Fish oil has also been studied in combination with other
therapies. Gupta et al. [22] conducted a double blind,
randomized, placebo-controlled study in 20 patients with
mild to moderate psoriasis vulgaris. One group received10
fish oil capsules twice daily (for a daily total of 3.6 g of
EPA and 2.4 g of DHA), whereas controls received 10 cap-
sules of olive oil. Patients were given fish oil (or placebo)
for the first 3 weeks of the study (weeks 0–3). At this
point, concomitant twice-weekly therapy with suberythe-
mal doses of UVB phototherapy for the next 8 weeks was
initiated (weeks 3–11). For the last 4 weeks of the study
(weeks 11–15), only fish or olive oil was given.The total
body surface area (TBSA) was significantly lower at week
15 in the fish oil treated group compared with the olive oil
group (22 vs 45%) and greater clinical improvement (scale,
erythema, thickness) was also observed in the fish oil
group. Therefore, fish oil showed great benefit as an adju-
vant therapy with suberythemal doses of ultraviolet UVB.
In an open study of 30 patients with mild to moderate
plaque psoriasis, 15 patients were given topical tacalcitol,
a synthetic vitamin D3 analogue, and 2 daily capsules of
Oravex® (280 mg of EPA and 40 mg of DHA per capsule),
whereas the remaining 15 patients received topical treat-
ment with tacalcitol for 8 weeks. Supplementary treatment
with omega-3 fatty acids complemented topical treatment
and contributed significantly to reduction of PASI and in
reducing injury to the scalp itching, erythema, desquam-
ation, and infiltration of the treated areas [14]. In another
study, 25 patients with stable plaque psoriasis were ran-
domly assigned to the fish or placebo oil groups. The daily
intake of 10 fish oil capsules included 5.4 g of EPA and
3.6 g of DHA or 10 olive oil capsules, 3 times daily for
9 weeks. For the first 3 weeks both groups applied
betamethasone dipropionate cream (moderate potency
corticosteroid) (45 g/week) to the plaques of psoriasis
twice daily. No clinically significant improvement
occurred after fish oil supplementation [23].Intravenous omega-3 fatty acid lipid infusions pro-
duced a significant improvement over the shortest time
as compared to oral administration. Mayser et al. [16]
and Grimminger et al. [24] each conducted double blind,
randomized, controlled studies comparing the effect of
intravenous omega-3 fatty acids to omega-6 fatty acids
for the treatment of psoriasis. In the Mayser et al. [16]
study, eighty-three patients hospitalized for chronic
plaque-type psoriasis, participated in a 14-day trial. They
were randomly allocated to receive daily infusions with
either an omega-3 fatty acid-based lipid emulsion (Ome-
gavenous; 200 ml/day with 4.2 g of both EPA and DHA)
or a conventional omega-6 fatty acids emulsion (Lipove-
nous; EPA +DHA < 0.1 g/100 ml). The PASI scores de-
creased 11.2 ± 9.8 in the omega-3 group versus 7.5 ± 8.8 in
the omega-6 group (p = 0.048), with significantly better
improvement in the omega-3 group in erythema, scale,
and induration. In Grimminger et al. study [24], twenty
patients hospitalized for acute guttate psoriasis with a
minimum 10% of body surface area involvement (range
10–90%) received daily infusions with either an omega-3
fatty acid-based lipid emulsion (100 ml/day with 2.1 g of
EPA and 21 g of DHA) or a conventional omega-6 lipid
emulsion (EPA +DHA < 0.1 g/100 ml) for 10 days. The
omega-3 group demonstrated greater improvement across
all clinical scores for erythema, infiltration, desquamation,
compared with the omega-6 group.
Escobar et al. [25] treated 25 patients with plaque
psoriasis, applying topical fish oil (containing 15.8% EPA
and 10.1% DHA) or liquid paraffin under an occlusive
dressing daily for 4 weeks. Significant decreases in scale
score and thickness were found in the fish oil treated
group compared with control. No significant change in
erythema was found. On the other hand, Henneicke-von
Zepelin et al. [26] studied 52 patients with moderate
plaque psoriasis given topical omega-3 polyunsaturated
fatty acid (1 or 10%) therapy or placebo and have not
found any statistically significant difference between the
treatment and placebo groups for local PASI, TBSA
involvement, erythema, desquamation, induration, or
pruritus after 8 weeks.
Low-grade systemic inflammation associated with obes-
ity may worsen the clinical course of psoriasis. Guida et al.
[27] conducted a randomized control clinical trial study
with 44 obese patients (body mass index-BMI > 30 kg/m2)
with mild-to-severe plaque-type psoriasis treated with im-
munosuppressive drugs. The patients consumed for
6 months either their usual diet or an energy restricted
diet (20 kcal/kg/ideal body weight/day) enriched with n-3
polyunsaturated fatty acids (PUFAs) (average 2.6 g/d). All
patients continued their immunomodulation therapy
throughout the study. More specifically, subjects were
instructed to minimize their intake of n-6 PUFAs by eat-
ing less meat, eggs, whole grains, and cereals. At the same
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foods naturally rich in n-3 PUFAs such as seafood (salmon,
sardines, herring, and bluefish) and an n-3 rich margarine.
In the intervention group, BMI and waist circumference
decreased (p < 0.05) and these changes were associated with
significant reductions in serum triglycerides and serum
total- and LDL cholesterol levels (p < 0.05) and a greater
than 50% reduction of PASI was reached at 6 months.
The role of nutrition in the treatment of psoriasis has
been studied for many years. Recent evidence has con-
firmed that adherence to a healthy diet over time reduces
the risk of long-term inflammation [28]. The antioxidants
present in the diet, such as omega-3 from fish oil, some
vitamins (A, E, and C), and oligoelements (iron, copper,
manganese, zinc, and selenium), which decrease oxidative
stress and the production of reactive oxygen species,
might be of particular relevance mainly in a chronic
systemic inflammatory diseases, like psoriasis [29]. The
Mediterranean diet is a healthy diet it is characterized by a
high intake of fruit and vegetables, legumes, grains and
cereals, fish and seafood, and nuts; a low intake of dairy
products, meat and meat products; and a moderate
ethanol intake mainly in the form of wine and during
meals. Extra virgin olive oil (EVOO) is the main
added lipid and its increased consumption is reflected
in the high monounsaturated to saturated fatty acid
intake [28, 29]. However, there are few studies that
relate to the Mediterranean diet with psoriasis.
The feed can influence psoriasis in two ways—as a cause
of metabolic disorders and in disease treatment and pre-
vention [30].Thus, the nutritional care of patients with
psoriasis, along with control of biochemical and anthropo-
metric variables, ensures greater clinical stability to these
individuals, preventing chronic non-communicable
diseases (NCD), commonly associated with the disease
and providing greater longevity with quality. However,
despite the fact that nutrition might be considered an
aadjunctive tool for the treatment of psoriasis, and fish oil
may influence both aforementioned conditions, there are
no national or international guidelines that recommend
an adequate diet or supplementation for such patients.
In sum, the majority of the studies analysed were
double-blind, randomized, and placebo-controlled, varying
from 4 weeks to 4 months and with doses between
640 mg and 5.4 g of the active substances (EPA and
DHA). Some studies used fish oil supplementation with
other therapies, in the topic form or as short-term intra-
venous infusion.
Conclusions
Taken together, the majority of the studies showed that n-3
polyunsaturated fatty acids, mainly from marine origin,
have beneficial effects and can be utilized as adjuvant ther-
apy in psoriasis treatment. Both oral and intravenousadministration of fish oil n-3 polyunsaturated fatty acids
had positive effects. However, further studies are warranted
to answer many intriguing questions, for instance, the ideal
quantity of fish oil to be utilized, the effect on different
forms and severity of psoriasis and last, but not least, the
consequences of using fish oil n-3 polyunsaturated fatty
acids on the cardiovascular features of patients with
psoriasis.
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